|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| PharmaWatch: IDI | 1 | 1 |
| THIS MONTH'S HIGHLIGHTS | 1 | 1 |
| Table: Key IDI Announcements, May 15, 2003-June 14, 2003 | 1 | 1 |
| IDI News Round-up | 1 | 2 |
| Arthritis | 3 | 1 |
| Opinion | 3 | 1 |
| Amgen: Enbrel rises while Kineret sinks | 3 | 1 |
| Amgen has reported positive trial data for its top-selling rheumatoid arthritis drug, Enbrel. | 3 | 1 |
| Table: Arthritis News Headlines June 15, 2003-July 14, 2003 | 4 | 1 |
| R&D Update | 4 | 1 |
| FDA approves expanded indication for Aventis' Arava | 4 | 2 |
| Phase III rheumatoid arthritis study shows Remicade plus methotrexate superior to standard therapy | 5 | 1 |
| Small-molecule compound shows positive response in rheumatoid arthritis model | 5 | 2 |
| Dimethaid presents positive head-to- head data on Pennsaid, wins EU approvals | 6 | 2 |
| Pfizer's Celebrex preferred by patients over acetaminophen for control of osteoarthritis pain | 7 | 1 |
| Abbott presents new data supporting Humira | 7 | 1 |
| Asthma | 8 | 1 |
| Opinion | 8 | 1 |
| Allergies: nothing to sneeze at | 8 | 1 |
| A report by the Royal College of Physicians reveals a looming allergy crisis in the UK | 8 | 1 |
| Table: Asthma News Headlines June 15, 2003-July 14, 2003 | 9 | 1 |
| Patents and Licensing Update | 9 | 1 |
| APT receives patent for targeted delivery of hydroxychloroquine for inflammatory diseases | 9 | 1 |
| Merck licenses Amrad technology to develop new asthma drugs | 9 | 2 |
| Regulatory and R&D Update | 10 | 1 |
| FDA approves Xolair as a new breakthrough treatment for asthma | 10 | 1 |
| aaiPharma files SNDA for Brethine Ampuls | 10 | 1 |
| SR Pharma completes enrollment of phase II trial for asthma | 10 | 2 |
| Diabetes | 12 | 1 |
| Opinion | 12 | 1 |
| Nektar: Exubera trials alleviate concerns | 12 | 1 |
| Nektar Therapeutics has released positive results from trials of inhalable insulin Exubera | 12 | 1 |
| Eli Lilly/GSK: glitazone benefits to drive growth | 12 | 1 |
| New studies demonstrate the long-term efficacy of Actos and cardiovascular benefits of Avandia | 12 | 1 |
| New studies demonstrate the long-term efficacy of Actos and cardiovascular benefits of Avandia (CON | 13 | 1 |
| Table: Diabetes News Headlines June 15, 2003-July 14, 2003 | 14 | 1 |
| R&D Update | 14 | 1 |
| Data supports use of Lantus for treatment of diabetes | 14 | 2 |
| Eli Lilly and Amylin achieve encouraging results in exenatide diabetes study | 15 | 1 |
| Exubera demonstrates better glycemic control compared with rosiglitazone in type 2 diabetes | 15 | 2 |
| Emisphere achieves promising results in oral insulin studies | 16 | 2 |
| Novocell achieves impressive results with islet cell implants in primate models of diabetes | 17 | 1 |
| Regulatory and Licensing Update | 17 | 1 |
| Aventis and Zealand Pharma enter diabetes licensing agreement | 17 | 2 |
| Aventis files EU and US regulatory submissions for glulisine | 18 | 1 |
| Other IDI | 19 | 1 |
| Table: Other IDI News Headlines June 15, 2003-July 14, 2003 | 19 | 1 |
| Growth Disorders Update | 19 | 1 |
| Alkermes and Eli Lilly present clinical data for inhaled form of human growth hormone | 19 | 2 |
| Insmed receives European orphan drug designation for growth disorder treatment | 20 | 1 |
| Insmed launches pivotal phase III growth hormone insensitivity trial | 20 | 1 |
| European Union grants new indication for Pfizer's Genotropin | 20 | 2 |
| Skin Disorders Update | 21 | 1 |
| New data shows Amevive provides relief from psoriasis for a median of seven months | 21 | 1 |
| Serono presents positive results for onercept in psoriasis and psoriatic arthritis | 21 | 1 |
| SkinMedica and Dow Pharmaceutical Sciences to develop prescription dermatology product | 21 | 2 |
| Amgen and Wyeth advance Enbrel to regulatory review in psoriasis | 22 | 1 |
| Vicuron happy with phase I safety trial of acne treatment | 22 | 2 |
| Ranbaxy gains FDA approval for additional Isotretinoin dosage | 23 | 1 |
| FEATURE ANALYSIS | 24 | 1 |
| Diabetes: Statins offer a new area of treatment | 24 | 1 |
| Market leaders | 24 | 1 |
| A shot in the arm | 24 | 1 |
| Significant findings | 24 | 2 |
| New battleground, same players | 25 | 1 |
| Related Report: | 25 | 1 |
| Convincing the healthy to get vaccinated | 25 | 1 |
| Limited approval presents challenge | 25 | 2 |
| Flu vaccine shortfalls could benefit FluMist | 26 | 1 |
| Effective marketing and education campaigns will be key | 26 | 1 |
| Nasal delivery will drive growth | 26 | 1 |
| COMPANY SPOTLIGHT-Aventis | 27 | 1 |
| Table/Chart: Key Facts | 27 | 1 |
| Company Overview | 27 | 1 |
| Business Description | 27 | 2 |
| Igor Landau | 28 | 1 |
| Table/Chart: Executive's Data | 28 | 1 |
| Richard J Markham | 28 | 1 |
| Patrick Langlois | 28 | 1 |
| SWOT Analysis | 28 | 1 |
| Table: SWOT Analysis | 29 | 1 |
| Strengths | 29 | 1 |
| Weaknesses | 29 | 2 |
| Opportunities | 30 | 1 |
| Threats | 30 | 1 |
| Major Products & Services | 31 | 1 |
| Table/Chart: PHARMACEUTICALS | 31 | 1 |
| Table/Chart: KEY PRODUCTS UNDER REGULATORY REVIEW OR IN CLINICAL DEVELOPMENT | 31 | 1 |
| Table/Chart: MERIAL, A JOINT VENTURE WITH MERCK & CO. | 32 | 1 |
| Products & Services Analysis | 32 | 1 |
| Prescription Pharmaceuticals | 32 | 1 |
| Human Vaccines | 33 | 1 |
| Merial | 33 | 1 |
| Non-Core Activities | 33 | 1 |
| Geographical Revenue | 33 | 1 |
| Table/Chart: Competitor Analysis | 33 | 1 |
